ArticleScientific reports2025
Lack of association between the rs1842681 polymorphism of the LOC105372028 gene and functional outcomes after stroke.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The rs1842681 polymorphism of the LOC105372028 gene was found to correlate with a 3-month functional stroke outcome in a genome-wide association study meta-analysis performed by the GISCOME study. Although the STRONG study confirmed these results, a study in a Chinese population reported no such correlation. We prospectively examined the correlation between the rs1842681 polymorphism of the LOC105372028 gene and the 3-month ischemic stroke functional outcome in a Polish population. In 1037 IBioStroke participants, we examined two multivariate logistic regression models, predicting excellent (mRS: 0-1 vs. 2-6) and good (mRS: 0-2 vs. 3-6) outcomes. In an univariate analysis the rs1842681 polymorphism, among several other parameters available in acute stroke, was associated with an excellent outcome in an additive model (AG vs. GG genotype distribution) (OR = 0.74; 95%CI: 0.57-0.97, p = 0.027), in a dominant model (AG + AA vs. GG) (OR = 0.75; 95%CI: 0.58-0.96, p = 0,025) and in A/G allele frequencies (OR = 0.81, 95%CI:0.66-0.99, p = 0.044), however, it was not associated with good outcome in an additive, dominant and recessive models, as well as the A/G allele frequencies. The multivariate analyses, including additive mode (AM) and dominant mode (DM) of inheritance showed, that excellent outcome was associated with younger age (AM: OR = 0.95; 95%CI:0.94-0.97, p < 0.001; DM: OR = 0.95; 95%CI:0.94-0.97, p < 0.001), longer education (AM: OR = 1.07; 95%CI:1.01-1.14, p = 0.019; AD: OR = 1.07; 95%CI:1.01-1.14, p = 0.019), neurological improvement within 24 h (AM: OR = 1.11; 95%CI: 1.08-1.15, p < 0.001; AD: OR = 1.11; 95%CI: 1.07-1.15, p < 0.001), absence of hemorrhagic transformation (AM: OR = 0.48; 95%CI: 0.30-0.77, p = 0.003; AD: OR = 0.49; 95%CI: 0.31-0.79, p = 0.003), absence of infection (AM: OR = 0.21; 95%CI: 0.14-0.31, p < 0.001; AD: OR = 0.21; 95%CI: 0.14-0.31, p < 0.001), lower WBC count (AM: OR = 0.90; 95%CI:0.85-0.96, p < 0.001; AD: OR = 0.90; 95%CI:0.85-0.96, p < 0.001), and lower glucose levels (AM: OR = 1.00; 95%CI: 0.99-1.00, p = 0.035; DM: OR = 1.00; 95%CI: 0.99-1.00, p = 0.037); while good outcome - with younger age (OR = 0.96; 95%CI: 0.94-0.97, p < 0.001); longer education (OR = 1.10; 95%CI:1.03-1.17, p = 0.004); neurological improvement within 24 h (OR = 1.13; 95%CI: 1.09-1.17, p < 0.001), absence of infection (OR = 0.20; 95%CI: 0.14-0.30, p < 0.001) and lower WBC count (OR = 0.87; 95%CI: 0.82-0.93, p < 0.001). The influence of the rs1842681 variant on the 3-month functional stroke outcome was not confirmed in the Polish population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.